MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Isoray Balance Sheet 2011-2026 | ISR
Annual Balance Sheet Isoray
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-28.4 M | -59.2 M | -8.41 M | -20.6 M | -59.6 M | - | -5.33 M | -2.6 M | -5.93 M | -10.1 M | -5.23 M | -7.68 M | -2.9 M | -2.67 M | -2.11 M |
Long Term Debt |
1.62 M | 1.43 M | 780 K | 116 K | 524 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
623 K | 957 K | 46 K | 276 K | 252 K | 236 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 621 K | 590 K | 561 K | 607 K | 1.13 M | 1.44 M | 896 K | 1.04 M | 662 K |
Total Current Liabilities |
28.7 M | 18.2 M | 15.7 M | 3.12 M | 1.8 M | 1.58 M | 1.12 M | 1.84 M | 1.11 M | 1.09 M | 1.09 M | 1.15 M | 793 K | 649 K | - |
Total Liabilities |
59.9 M | 50.4 M | 22.7 M | 3.45 M | 3.01 M | 2.98 M | 1.74 M | 2.42 M | 1.67 M | 1.7 M | 2.22 M | 2.59 M | 1.69 M | 1.69 M | 1.44 M |
Retained Earnings |
-335 M | -232 M | -152 M | -106 M | -91.3 M | -87.9 M | -84.5 M | -79.3 M | -72.6 M | -66.4 M | -61.7 M | -58.1 M | -52.1 M | -48.2 M | -44.7 M |
Total Assets |
267 M | 341 M | 97.9 M | 58.1 M | 70.4 M | 8.7 M | 9.42 M | 7.46 M | 12.3 M | 18.1 M | 23 M | 26.5 M | 7.06 M | 7.51 M | 7.89 M |
Cash and Cash Equivalents |
30.6 M | 61.6 M | 9.24 M | 21 M | 60.4 M | 2.39 M | 5.33 M | 2.6 M | 5.93 M | 10.1 M | 5.23 M | 7.68 M | 2.9 M | 2.67 M | 2.11 M |
Book Value |
207 M | 291 M | 75.2 M | 54.6 M | 67.4 M | 5.72 M | 7.68 M | 5.03 M | 10.6 M | 16.4 M | 20.8 M | 24 M | 5.37 M | 5.82 M | 6.45 M |
Total Shareholders Equity |
207 M | 291 M | 75.2 M | 54.6 M | 67.4 M | 5.72 M | 7.68 M | 5.03 M | 10.6 M | 16.4 M | 20.8 M | 24 M | 5.37 M | 5.82 M | 6.45 M |
All numbers in USD currency
Quarterly Balance Sheet Isoray
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.64 M | 1.65 M | 1.43 M | 1.69 M | 1.7 M | 1.71 M | 780 K | 1.74 M | 1.77 M | 1.79 M | 116 K | 186 K | 256 K | 324 K | 392 K | 459 K | 524 K | 524 K | 652 K | 715 K | 769 K | 769 K | 889 K | 948 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
52.6 M | 45 M | 50.4 M | 62.7 M | 44.9 M | 48.4 M | 22.7 M | 11.7 M | 11.5 M | 9.62 M | 3.45 M | 4.84 M | 3.16 M | 2.91 M | 2.86 M | 2.95 M | 3.01 M | 3.01 M | 2.74 M | 2.93 M | 2.98 M | 2.98 M | 2.79 M | 3.17 M | 1.74 M | 1.74 M | 2.25 M | 2.24 M | 2.42 M | 2.42 M | 1.51 M | 1.64 M | 1.67 M | 1.67 M | 1.42 M | 1.71 M | 1.7 M | 1.7 M | 2.19 M | 2.07 M | 2.22 M | 2.22 M | 2.06 M | 2.12 M | 2.59 M | 2.59 M | 1.7 M | 1.92 M | 1.69 M | 1.69 M | 1.69 M | 1.5 M | 1.69 M | 1.69 M | 1.77 M | 1.6 M | 1.44 M | 1.44 M |
Retained Earnings |
-297 M | -271 M | -232 M | -192 M | -176 M | -165 M | -152 M | -128 M | -117 M | -106 M | -106 M | -103 M | -98.6 M | -96.5 M | -95.2 M | -93.6 M | -91.3 M | -91.3 M | -89.5 M | -88.7 M | -87.9 M | -87.9 M | -86.2 M | -85.3 M | -84.5 M | -84.5 M | -82.3 M | -80.9 M | -79.3 M | -79.3 M | -75.6 M | -74.2 M | -72.6 M | -72.6 M | -69.4 M | -67.9 M | -66.4 M | -66.4 M | -64.1 M | -62.8 M | -61.7 M | -61.7 M | -59.7 M | -58.8 M | -58.1 M | -58.1 M | -54.3 M | -53.4 M | -52.1 M | -52.1 M | -50.4 M | -49.2 M | -48.2 M | -48.2 M | -46.5 M | -45.8 M | -44.7 M | -44.7 M |
Total Assets |
295 M | 311 M | 341 M | 391 M | 386 M | 278 M | 97.9 M | 111 M | 120 M | 128 M | 58.1 M | 62.5 M | 64.4 M | 66.1 M | 67.3 M | 68.7 M | 70.4 M | 70.4 M | 15.5 M | 8.02 M | 8.7 M | 8.7 M | 8.93 M | 10.1 M | 9.42 M | 9.42 M | 11.9 M | 13.3 M | 7.46 M | 7.46 M | 9.38 M | 10.8 M | 12.3 M | 12.3 M | 15 M | 16.7 M | 18.1 M | 18.1 M | 20.7 M | 21.9 M | 23 M | 23 M | 24.6 M | 25.5 M | 26.5 M | 26.5 M | 8.19 M | 9.33 M | 7.06 M | 7.06 M | 8.72 M | 9.66 M | 7.51 M | 7.51 M | 8.45 M | 7.02 M | 7.89 M | 7.89 M |
Cash and Cash Equivalents |
26.8 M | 28.8 M | 61.6 M | 226 M | 252 M | 142 M | 9.24 M | 18 M | 28.3 M | 36.5 M | 21 M | 19 M | 55.9 M | 58.9 M | 60.4 M | 61.7 M | 63.8 M | 63.8 M | 9.58 M | 1.94 M | 9.58 M | 1.94 M | 3.18 M | 4.58 M | 3.18 M | 4.58 M | 3.2 M | 2.19 M | 3.2 M | 2.19 M | 2.95 M | 3.96 M | 2.95 M | 3.96 M | 6.67 M | 8.46 M | 6.67 M | 8.46 M | 679 K | 1.59 M | 679 K | 1.59 M | 1.34 M | 2.08 M | 1.34 M | 2.08 M | 4.41 M | 5.28 M | 4.41 M | 5.28 M | 4.44 M | 5.03 M | 4.44 M | 5.03 M | 3.44 M | 1.59 M | 3.38 M | 1.59 M |
Book Value |
242 M | 266 M | 291 M | 328 M | 341 M | 230 M | 75.2 M | 98.8 M | 109 M | 118 M | 54.6 M | 57.7 M | 61.3 M | 63.2 M | 64.4 M | 65.8 M | 67.4 M | 67.4 M | 12.8 M | 5.1 M | 5.72 M | 5.72 M | 6.14 M | 6.96 M | 7.68 M | 7.68 M | 9.66 M | 11.1 M | 5.03 M | 5.03 M | 7.87 M | 9.15 M | 10.6 M | 10.6 M | 13.6 M | 15 M | 16.4 M | 16.4 M | 18.6 M | 19.8 M | 20.8 M | 20.8 M | 22.5 M | 23.4 M | 24 M | 24 M | 6.49 M | 7.41 M | 5.37 M | 5.37 M | 7.02 M | 8.16 M | 5.82 M | 5.82 M | 6.68 M | 5.42 M | 6.45 M | 6.45 M |
Total Shareholders Equity |
242 M | 266 M | 291 M | 328 M | 341 M | 230 M | 75.2 M | 98.8 M | 109 M | 118 M | 54.6 M | 57.7 M | 61.3 M | 63.2 M | 64.4 M | 65.8 M | 64.4 M | 65.8 M | 12.8 M | 12.8 M | 12.8 M | 5.1 M | 6.14 M | 6.14 M | 6.14 M | 6.96 M | 9.66 M | 9.66 M | 9.66 M | 11.1 M | 7.87 M | 9.15 M | 7.87 M | 9.15 M | 13.6 M | 15 M | 16.4 M | 16.4 M | 18.6 M | 19.8 M | 20.8 M | 20.8 M | 22.5 M | 23.4 M | 24 M | 24 M | 6.49 M | 7.41 M | 5.37 M | 5.37 M | 7.02 M | 8.16 M | 5.82 M | 5.82 M | 6.68 M | 5.42 M | 6.45 M | 6.45 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Isoray, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
$ 30.04 | -1.31 % | $ 1.43 B |  USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.66 | -0.09 % | $ 435 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
$ 78.09 | 0.37 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 4.85 | -3.19 % | $ 215 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
ICU Medical
ICUI
|
$ 130.44 | 2.74 % | $ 3.21 B | USA |
 |
The Cooper Companies
COO
|
$ 72.05 | 1.42 % | $ 14.3 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 116.7 | 2.58 % | $ 3.73 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 484.71 | 0.26 % | $ 173 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 102.45 | 3.55 % | $ 4.96 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 163.23 | 1.85 % | $ 47 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 60.45 | 1.22 % | $ 3.04 B | USA |
 |
electroCore
ECOR
|
$ 6.94 | 10.33 % | $ 38.3 K | USA |
 |
Masimo Corporation
MASI
|
$ 175.82 | 0.24 % | $ 9.37 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.79 | 2.25 % | $ 202 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.93 | -2.15 % | $ 26.5 M | USA |
 |
ResMed
RMD
|
$ 234.32 | 1.61 % | $ 34.2 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.83 | 3.24 % | $ 4.34 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.34 | 1.17 % | $ 200 M | USA |
 |
Baxter International
BAX
|
$ 17.63 | 3.04 % | $ 9.04 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 110.16 | 0.85 % | $ 4.92 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.2 | 0.66 % | $ 884 M | USA |
 |
Nephros
NEPH
|
$ 2.95 | 1.03 % | $ 30.6 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 70.0 | 1.19 % | $ 4.14 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.04 | -2.88 % | $ 223 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 112.74 | 1.79 % | $ 2.55 B | USA |
 |
Pro-Dex
PDEX
|
$ 48.61 | -2.06 % | $ 160 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.73 | -0.18 % | $ 27.8 M |  Israel |
 |
West Pharmaceutical Services
WST
|
$ 239.85 | -0.19 % | $ 17.3 B | USA |
 |
Repligen Corporation
RGEN
|
$ 119.84 | 4.1 % | $ 6.68 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.1 % | $ 21 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 22.19 | 1.63 % | $ 1.5 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 17.67 | -2.27 % | $ 876 M | USA |
 |
Stereotaxis
STXS
|
$ 1.92 | 0.52 % | $ 175 M | USA |
 |
STERIS plc
STE
|
$ 220.32 | 0.49 % | $ 21.7 B | USA |
 |
Utah Medical Products
UTMD
|
$ 65.21 | 2.39 % | $ 237 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.22 | 4.18 % | $ 2.44 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 5.53 % | $ 23.1 M | USA |